Spots Global Cancer Trial Database for unrelated donors
Every month we try and update this database with for unrelated donors cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System | NCT00520130 | Myelodysplastic... Hodgkin's Lymph... Non-Hodgkin's D... Acute Leukemia Multiple Myelom... | Rituximab Cyclosporine Allogenic stem ... Conditioning Ch... TMS FLAG EPOCH-F Alemtuzumab | 18 Years - 74 Years | National Institutes of Health Clinical Center (CC) | |
| Visilizumab for the Prevention of Graft-versus-Host Disease After Allogeneic Hematopoietic Cell Transplantation | NCT00720629 | Graft Versus Ho... | Visilizumab Tacrolimus Methotrexate Antithymocyte g... Tacrolimus Methotrexate | 18 Years - 60 Years | H. Lee Moffitt Cancer Center and Research Institute | |
| Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System | NCT00520130 | Myelodysplastic... Hodgkin's Lymph... Non-Hodgkin's D... Acute Leukemia Multiple Myelom... | Rituximab Cyclosporine Allogenic stem ... Conditioning Ch... TMS FLAG EPOCH-F Alemtuzumab | 18 Years - 74 Years | National Institutes of Health Clinical Center (CC) | |
| Visilizumab for the Prevention of Graft-versus-Host Disease After Allogeneic Hematopoietic Cell Transplantation | NCT00720629 | Graft Versus Ho... | Visilizumab Tacrolimus Methotrexate Antithymocyte g... Tacrolimus Methotrexate | 18 Years - 60 Years | H. Lee Moffitt Cancer Center and Research Institute | |
| HLA-Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation With Reduced Dose Post Transplantation Cyclophosphamide GvHD Prophylaxis | NCT06001385 | Acute Lymphobla... Acute Myeloid L... Acute Leukemia Myelodysplastic... Chronic Myeloid... Chronic Lymphoc... Myeloproliferat... Lymphoma Chronic Myelomo... Pro-Lymphocytic... Myelofibrosis | Busulfan Fludarabine PBSC Hematopoie... Post-Transplant... Mesna Tacrolimus Mycophenolate M... Patient Reporte... Melphalan Total-body irra... Cyclophosphamid... | 18 Years - | Center for International Blood and Marrow Transplant Research | |
| HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide | NCT04904588 | Acute Lymphobla... Acute Myelogeno... Mixed Phenotype... Acute Leukemia Myelodysplastic... Chronic Myeloge... Chronic Lymphoc... Lymphoma | Busulfan Busulfan Fludarabine Total-body irra... Cyclophosphamid... Melphalan PBSC Hematopoie... Bone Marrow Hem... Post-transplant... Mesna Tacrolimus Mycophenolate M... Patient-Reporte... | 1 Year - | Center for International Blood and Marrow Transplant Research | |
| Study of Palifermin (Kepivance) in Persons Undergoing Unrelated Donor Allogeneic Hematopoietic Cell Transplantation | NCT02356159 | Myelodysplastic... Hodgkin's Lymph... Non-Hodgkin's L... Acute Leukemia Multiple Myelom... | Rituximab Conditioning ch... TMS FLAG EPOCH-F Hematopoietic s... Palifermin | 18 Years - | National Institutes of Health Clinical Center (CC) |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
